Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: Reconciling the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health Outcomes) trial with previous surrogate endpoint trials

Journal of the American College of Cardiology

Volumn 59, Issue 23, 2012, Pages 2058-2064

  Michos, Erin D ^a   Sibley, Christopher T ^a,b   Baer, Jefferson T ^c   Blaha, Michael J ^a   Blumenthal, Roger S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AIM HIGH; HDL; lipids; niacin; review

Indexed keywords

ANACETRAPIB; ANTIOXIDANT; ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; DALCETRAPIB; ETC 216; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; LIVER X RECEPTOR AGONIST; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; NICOTINIC ACID PLUS SIMVASTATIN; OMEGA 3 FATTY ACID; PEPTIDOMIMETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PLACEBO; SIMVASTATIN; TORCETRAPIB;

ACUTE CORONARY SYNDROME; ADJUVANT THERAPY; ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY; COMBINATION CHEMOTHERAPY; CORONARY ARTERY OBSTRUCTION; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; HUMAN; HYPERCHOLESTEROLEMIA; MONOTHERAPY; PREDICTION; PRIORITY JOURNAL; REMISSION; REVIEW; RISK REDUCTION; UNSPECIFIED SIDE EFFECT;

AGED; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIPOPROTEINS, HDL; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NIACIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; RISK ASSESSMENT; TREATMENT OUTCOME; TRIGLYCERIDES; WORLD HEALTH;

EID: 84861606700     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2012.01.045     Document Type: Review

References (27)

1. G.F. Watts, D.C. Chan Of mice and men Blowing away the cobwebs from the mechanisms of action of niacin on HDL metabolism Arterioscler Thromb Vasc Biol 28 2008 1892 1895
2. E.M. deGoma, D.J. Rader Novel HDL-directed pharmacotherapeutic strategies Nat Rev Cardiol 8 2011 266 277
3. B.G. Brown, X.Q. Zhao, A. Chait Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease N Engl J Med 345 2001 1583 1592
4. G. Brown, J.J. Albers, L.D. Fisher Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B N Engl J Med 323 1990 1289 1298
5. P.L. Canner, K.G. Berge, N.K. Wenger Fifteen year mortality in Coronary Drug Project patients; long term benefit with niacin J Am Coll Cardiol 8 1986 1245 1255
6. E. Bruckert, J. Labreuche, P. Amarenco Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis Atherosclerosis 210 2010 353 361
7. A.J. Taylor, L.E. Sullenberger, H.J. Lee, J.K. Lee, K.A. Grace Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER 2): a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins Circulation 110 2004 3512 3517
8. A.J. Taylor, H.J. Lee, L.E. Sullenberger The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3 Current Med Res Opin 22 2006 2243 2250
9. A.J. Taylor, T.C. Villines, E.J. Stanek Extended-release Niacin or Ezetimibe and carotid intima-media thickness N Engl J Med 361 2009 2113 2122
10. J.M. Lee, M.D. Robson, L.M. Yu Effects of high dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo controlled, magnetic resonance imaging study J Am Coll Cardiol 54 2009 1787 1794
11. C.T. Sibley, I. Gottlieb, C. Cox Comparative effect of statins vs. niacin on MRI Measured regression of carotid atherosclerosis in a randomized clinical trial: the NIA Plaque Study (abstr) Circulation 120 2009 S376
12. AIM-HIGH Investigators Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 2011 2255 2267
13. T.C. Villines, E.J. Stanek, P.J. Devine The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and impact of medication adherence, dose, and treatment duration J Am Coll Cardiol 55 2010 2721 2726
14. P.J. Barter, M. Caulfield, M. Eriksson Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 357 2007 2109 2122
15. K. Sharma, M.J. Blaha, R.S. Blumenthal, K. Musunuru Clinical and research applications of carotid intima-media thickness Am J Cardiol 103 2009 1316 1320
16. A.R. Folsom, R.A. Kronmal, R.C. Detrano Coronary artery calcification compared with carotid intima-media thickness in the prediction of cardiovascular disease incidence Arch Intern Med 168 2008 1333 1339
17. H.N. Hodis, W.J. Mack, R.A. Lobo Estrogen in the prevention of atherosclerosis A randomized, double-blind, placebo-controlled trial Ann Intern Med 135 2001 939 953
18. M.R. Langenfeld, T. Forst, C. Hohberg Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study Circulation 111 2005 2525 2531
19. S.E. Nissen, K. Wolski Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 356 2007 2457 2471
20. M.A. Espeland, D.H. O'Leary, J.G. Terry Carotid intimal thickness as a surrogate for cardiovascular disease events in trials of HMG-CoA reductase inhibitors Curr Control Trials Cardiovasc Med 6 2005 3
21. P. Costanzo, P. Perrone-Filardi, E. Vassallo Does carotid intima-media thickness regression predict reduction of cardiovascular events? A meta-analysis of 41 randomized trials J Am Coll Cardiol 56 2010 2006 2020
22. The ACCORD Study Group Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med 362 2010 1563 1574
23. M. Yokoyama, H. Origasa, M. Matsuzaki Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomized open-label, blinded endpoint analysis Lancet 369 2007 1090 1098
24. B. Rauch, R. Schiele, S. Schneider OMEGA, a randomized, placebo-controlled trial to test the effects of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction Circulation 122 2010 2152 2159
25. C.P. Cannon, R.P. Giugliano, M.A. Blazing Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndrome Am Heart J 156 2008 826 832
26. J.L. Fleg, M. Mete, B.V. Howard Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetic Study) trial J Am Coll Cardiol 52 2008 2198 2205
27. P. Barter, A.M. Gotto, J.C. LaRosa HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events N Engl J Med 357 2007 1301 1310